{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T16:55:14Z","timestamp":1776531314561,"version":"3.51.2"},"reference-count":200,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,30]]},"DOI":"10.7759\/cureus.19152","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T01:53:22Z","timestamp":1635645202000},"source":"Crossref","is-referenced-by-count":6,"title":["Critical Updates on Chronic Hepatitis B Virus Infection in 2021"],"prefix":"10.7759","author":[{"given":"Cyriac A","family":"Philips","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Ahamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinsha K","family":"Abduljaleel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasidharan","family":"Rajesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.039","article-title":"When (and when not) to treat patients with HBV infection","volume":"17","author":"Fricker ZP","year":"2019","unstructured":"Fricker ZP, Reddy KR. When (and when not) to treat patients with HBV infection. Clin Gastroenterol Hepatol. 2019, 17:2644-7. 10.1016\/j.cgh.2019.05.039","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7027169","article-title":"A systematic review of the current hepatitis B viral infection and hepatocellular carcinoma situation in Mediterranean countries","volume":"2020","author":"Madihi S","year":"2020","unstructured":"Madihi S, Syed H, Lazar F, Zyad A, Benani A. A systematic review of the current hepatitis B viral infection and hepatocellular carcinoma situation in Mediterranean countries. Biomed Res Int. 2020, 2020:7027169. 10.1155\/2020\/7027169","journal-title":"Biomed Res Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13283","article-title":"The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: a systematic review and meta-analysis","volume":"27","author":"Fonseca MA","year":"2020","unstructured":"Fonseca MA, Ling JZ, Al-Siyabi O, Co-Tanko V, Chan E, Lim SG. The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: a systematic review and meta-analysis. J Viral Hepat. 2020, 27:650-62. 10.1111\/jvh.13283","journal-title":"J Viral Hepat"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1476","article-title":"How durable is functional cure (hepatitis B surface antigen loss) in patients with chronic hepatitis B treated with current antivirals?","volume":"4","author":"Loglio A","year":"2020","unstructured":"Loglio A, Lampertico P. How durable is functional cure (hepatitis B surface antigen loss) in patients with chronic hepatitis B treated with current antivirals?. Hepatol Commun. 2020, 4:5-7. 10.1002\/hep4.1476","journal-title":"Hepatol Commun"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0210-5","article-title":"HIV, HCV and HBV: a review of parallels and differences","volume":"7","author":"Leoni MC","year":"2018","unstructured":"Leoni MC, Ustianowski A, Farooq H, Arends JE. HIV, HCV and HBV: a review of parallels and differences. Infect Dis Ther. 2018, 7:407-19. 10.1007\/s40121-018-0210-5","journal-title":"Infect Dis Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-019-00236-3","article-title":"Updates on chronic HBV: current challenges and future goals","volume":"17","author":"Lee HM","year":"2019","unstructured":"Lee HM, Banini BA. Updates on chronic HBV: current challenges and future goals. Curr Treat Options Gastroenterol. 2019, 17:271-91. 10.1007\/s11938-019-00236-3","journal-title":"Curr Treat Options Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104973","article-title":"HBV evolution and genetic variability: impact on prevention, treatment and development of antivirals","volume":"186","author":"Glebe D","year":"2021","unstructured":"Glebe D, Goldmann N, Lauber C, Seitz S. HBV evolution and genetic variability: impact on prevention, treatment and development of antivirals. Antiviral Res. 2021, 186:104973. 10.1016\/j.antiviral.2020.104973","journal-title":"Antiviral Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000360946","article-title":"Molecular virology of hepatitis B virus and targets for antiviral intervention","volume":"57","author":"Glebe D","year":"2014","unstructured":"Glebe D, K\u00f6nig A. Molecular virology of hepatitis B virus and targets for antiviral intervention. Intervirology. 2014, 57:134-40. 10.1159\/000360946","journal-title":"Intervirology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i37.13293","article-title":"Update on hepatitis B virus infection","volume":"20","author":"You CR","year":"2014","unstructured":"You CR, Lee SW, Jang JW, Yoon SK. Update on hepatitis B virus infection. World J Gastroenterol. 2014, 20:13293-305. 10.3748\/wjg.v20.i37.13293","journal-title":"World J Gastroenterol"},{"key":"ref10","article-title":"Latest developments in the treatment of hepatitis B","volume":"62","author":"Dandri M","year":"2016","unstructured":"Dandri M, Petersen J. Latest developments in the treatment of hepatitis B. Minerva Gastroenterol Dietol. 2016, 62:88-102.","journal-title":"Minerva Gastroenterol Dietol"},{"key":"ref11","article-title":"Hepatitis B 2020","author":"Tripathi N","year":"2020","unstructured":"Tripathi N, Mousa OY. Hepatitis B 2020. StatPearls, Treasure Island; 2020."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: the virus and disease","volume":"49","author":"Liang TJ","year":"2009","unstructured":"Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009, 49:S13-21. 10.1002\/hep.22881","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.022","article-title":"High tolerance of hepatitis B virus to thermal disinfection","volume":"71","author":"K\u00f6nig A","year":"2019","unstructured":"K\u00f6nig A, Than TT, Todt D, Yoon SK, Steinmann J, Steinmann E, Windisch MP. High tolerance of hepatitis B virus to thermal disinfection. J Hepatol. 2019, 71:1249-51. 10.1016\/j.jhep.2019.08.022","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2020.01.003","article-title":"Hepatitis B: current status of therapy and future therapies","volume":"49","author":"Spyrou E","year":"2020","unstructured":"Spyrou E, Smith CI, Ghany MG. Hepatitis B: current status of therapy and future therapies. Gastroenterol Clin North Am. 2020, 49:215-38. 10.1016\/j.gtc.2020.01.003","journal-title":"Gastroenterol Clin North Am"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.058","article-title":"Insights from deep sequencing of the HBV genome-unique, tiny, and misunderstood","volume":"156","author":"McNaughton AL","year":"2019","unstructured":"McNaughton AL, D'Arienzo V, Ansari MA, et al.. Insights from deep sequencing of the HBV genome-unique, tiny, and misunderstood. Gastroenterology. 2019, 156:384-99. 10.1053\/j.gastro.2018.07.058","journal-title":"Gastroenterology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.009","article-title":"Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions","volume":"66","author":"Xia Y","year":"2017","unstructured":"Xia Y, Carpentier A, Cheng X, et al.. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. J Hepatol. 2017, 66:494-503. 10.1016\/j.jhep.2016.10.009","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9605252","article-title":"Stem cell-derived hepatocyte-like cells as model for viral hepatitis research","volume":"2019","author":"Wang J","year":"2019","unstructured":"Wang J, Qu B, Zhang F, Zhang C, Deng W, Dao Thi VL, Xia Y. Stem cell-derived hepatocyte-like cells as model for viral hepatitis research. Stem Cells Int. 2019, 2019:9605252. 10.1155\/2019\/9605252","journal-title":"Stem Cells Int"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1811064116","article-title":"Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization","volume":"116","author":"Iwamoto M","year":"2019","unstructured":"Iwamoto M, Saso W, Sugiyama R, et al.. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci U S A. 2019, 116:8487-92. 10.1073\/pnas.1811064116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.00074","article-title":"E-cadherin plays a role in hepatitis B virus entry through affecting glycosylated sodium-taurocholate cotransporting polypeptide distribution","volume":"10","author":"Hu Q","year":"2020","unstructured":"Hu Q, Zhang F, Duan L, et al.. E-cadherin plays a role in hepatitis B virus entry through affecting glycosylated sodium-taurocholate cotransporting polypeptide distribution. Front Cell Infect Microbiol. 2020, 10:74. 10.3389\/fcimb.2020.00074","journal-title":"Front Cell Infect Microbiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00393-13","article-title":"Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment","volume":"87","author":"Macovei A","year":"2013","unstructured":"Macovei A, Petrareanu C, Lazar C, Florian P, Branza-Nichita N. Regulation of hepatitis B virus infection by Rab5, Rab7, and the endolysosomal compartment. J Virol. 2013, 87:6415-27. 10.1128\/JVI.00393-13","journal-title":"J Virol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.03257","article-title":"Troglitazone impedes the oligomerization of sodium taurocholate cotransporting polypeptide and entry of hepatitis B virus into hepatocytes","volume":"9","author":"Fukano K","year":"2018","unstructured":"Fukano K, Tsukuda S, Oshima M, et al.. Troglitazone impedes the oligomerization of sodium taurocholate cotransporting polypeptide and entry of hepatitis B virus into hepatocytes. Front Microbiol. 2018, 9:3257. 10.3389\/fmicb.2018.03257","journal-title":"Front Microbiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104816","article-title":"Mechanisms of HBV immune evasion","volume":"179","author":"Kuipery A","year":"2020","unstructured":"Kuipery A, Gehring AJ, Isogawa M. Mechanisms of HBV immune evasion. Antiviral Res. 2020, 179:104816. 10.1016\/j.antiviral.2020.104816","journal-title":"Antiviral Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/cmi.13205","article-title":"Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis","volume":"22","author":"Herrscher C","year":"2020","unstructured":"Herrscher C, Pastor F, Burlaud-Gaillard J, et al.. Hepatitis B virus entry into HepG2-NTCP cells requires clathrin-mediated endocytosis. Cell Microbiol. 2020, 22:e13205. 10.1111\/cmi.13205","journal-title":"Cell Microbiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2014.12.020","article-title":"Study of the putative fusion regions of the preS domain of hepatitis B virus","volume":"1848","author":"Delgado CL","year":"2015","unstructured":"Delgado CL, N\u00fa\u00f1ez E, Y\u00e9lamos B, G\u00f3mez-Guti\u00e9rrez J, Peterson DL, Gavilanes F. Study of the putative fusion regions of the preS domain of hepatitis B virus. Biochim Biophys Acta. 2015, 1848:895-906. 10.1016\/j.bbamem.2014.12.020","journal-title":"Biochim Biophys Acta"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/tra.12389","article-title":"Fusion of enveloped viruses in endosomes","volume":"17","author":"White JM","year":"2016","unstructured":"White JM, Whittaker GR. Fusion of enveloped viruses in endosomes. Traffic. 2016, 17:593-614. 10.1111\/tra.12389","journal-title":"Traffic"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.04.004","article-title":"Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections","volume":"30","author":"Tu T","year":"2018","unstructured":"Tu T, Urban S. Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. Curr Opin Virol. 2018, 30:68-79. 10.1016\/j.coviro.2018.04.004","journal-title":"Curr Opin Virol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cells9061486","article-title":"Hepatitis B virus entry into cells","volume":"9","author":"Herrscher C","year":"2020","unstructured":"Herrscher C, Roingeard P, Blanchard E. Hepatitis B virus entry into cells. Cells. 2020, 9:10.3390\/cells9061486","journal-title":"Cells"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15381","article-title":"Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant","volume":"50","author":"Jiang B","year":"2019","unstructured":"Jiang B, Wu Q, Kuhnhenn L, et al.. Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant. Aliment Pharmacol Ther. 2019, 50:940-54. 10.1111\/apt.15381","journal-title":"Aliment Pharmacol Ther"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.98","article-title":"HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly","volume":"2","author":"Patel N","year":"2017","unstructured":"Patel N, White SJ, Thompson RF, et al.. HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly. Nat Microbiol. 2017, 2:17098. 10.1038\/nmicrobiol.2017.98","journal-title":"Nat Microbiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro.2017.81","article-title":"Viral infection: packing to leave","volume":"15","author":"York A","year":"2017","unstructured":"York A. Viral infection: packing to leave. Nat Rev Microbiol. 2017, 15:450-1. 10.1038\/nrmicro.2017.81","journal-title":"Nat Rev Microbiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02139-17","article-title":"Hepatitis B virus core protein dephosphorylation occurs during pregenomic RNA encapsidation","volume":"92","author":"Zhao Q","year":"2018","unstructured":"Zhao Q, Hu Z, Cheng J, et al.. Hepatitis B virus core protein dephosphorylation occurs during pregenomic RNA encapsidation. J Virol. 2018, 92:10.1128\/JVI.02139-17","journal-title":"J Virol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092023","article-title":"Intracellular trafficking of HBV particles","volume":"9","author":"Jiang B","year":"2020","unstructured":"Jiang B, Hildt E. Intracellular trafficking of HBV particles. Cells. 2020, 9:10.3390\/cells9092023","journal-title":"Cells"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.032","article-title":"The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids","volume":"68","author":"Osseman Q","year":"2018","unstructured":"Osseman Q, Gallucci L, Au S, et al.. The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids. J Hepatol. 2018, 68:441-8. 10.1016\/j.jhep.2017.10.032","journal-title":"J Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick A","year":"2015","unstructured":"Zlotnick A, Venkatakrishnan B, Tan Z, Lewellyn E, Turner W, Francis S. Core protein: a pleiotropic keystone in the HBV lifecycle. Antiviral Res. 2015, 121:82-93. 10.1016\/j.antiviral.2015.06.020","journal-title":"Antiviral Res"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00272-18","article-title":"Common and distinct capsid and surface protein requirements for secretion of complete and genome-free hepatitis B virions","volume":"92","author":"Ning X","year":"2018","unstructured":"Ning X, Luckenbaugh L, Liu K, Bruss V, Sureau C, Hu J. Common and distinct capsid and surface protein requirements for secretion of complete and genome-free hepatitis B virions. J Virol. 2018, 92:10.1128\/JVI.00272-18","journal-title":"J Virol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0678-0","article-title":"Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation","volume":"5","author":"Wei L","year":"2020","unstructured":"Wei L, Ploss A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol. 2020, 5:715-26. 10.1038\/s41564-020-0678-0","journal-title":"Nat Microbiol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12497-y","article-title":"Involvement of PUF60 in transcriptional and post-transcriptional regulation of hepatitis B virus pregenomic RNA expression","volume":"7","author":"Sun S","year":"2017","unstructured":"Sun S, Nakashima K, Ito M, et al.. Involvement of PUF60 in transcriptional and post-transcriptional regulation of hepatitis B virus pregenomic RNA expression. Sci Rep. 2017, 7:12874. 10.1038\/s41598-017-12497-y","journal-title":"Sci Rep"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006296","article-title":"Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA","volume":"13","author":"Liu Y","year":"2017","unstructured":"Liu Y, Nie H, Mao R, et al.. Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. PLoS Pathog. 2017, 13:e1006296. 10.1371\/journal.ppat.1006296","journal-title":"PLoS Pathog"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02203-18","article-title":"Peroxiredoxin 1, a novel HBx-interacting protein, interacts with exosome component 5 and negatively regulates hepatitis B virus (HBV) propagation through degradation of HBV RNA","volume":"93","author":"Deng L","year":"2019","unstructured":"Deng L, Gan X, Ito M, et al.. Peroxiredoxin 1, a novel HBx-interacting protein, interacts with exosome component 5 and negatively regulates hepatitis B virus (HBV) propagation through degradation of HBV RNA. J Virol. 2019, 93:10.1128\/JVI.02203-18","journal-title":"J Virol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0091-4","article-title":"RBM24 stabilizes hepatitis B virus pregenomic RNA but inhibits core protein translation by targeting the terminal redundancy sequence","volume":"7","author":"Yao Y","year":"2018","unstructured":"Yao Y, Yang B, Cao H, et al.. RBM24 stabilizes hepatitis B virus pregenomic RNA but inhibits core protein translation by targeting the terminal redundancy sequence. Emerg Microbes Infect. 2018, 7:86. 10.1038\/s41426-018-0091-4","journal-title":"Emerg Microbes Infect"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.07.019","article-title":"Hepatitis B virus: the challenge of an ancient virus with multiple faces and a remarkable replication strategy","volume":"158","author":"Caballero A","year":"2018","unstructured":"Caballero A, Tabernero D, Buti M, Rodriguez-Frias F. Hepatitis B virus: the challenge of an ancient virus with multiple faces and a remarkable replication strategy. Antiviral Res. 2018, 158:34-44. 10.1016\/j.antiviral.2018.07.019","journal-title":"Antiviral Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-6700-1_4","article-title":"Intracytoplasmic transport of hepatitis B virus capsids","volume":"1540","author":"Osseman Q","year":"2017","unstructured":"Osseman Q, Kann M. Intracytoplasmic transport of hepatitis B virus capsids. Methods Mol Biol. 2017, 1540:37-51. 10.1007\/978-1-4939-6700-1_4","journal-title":"Methods Mol Biol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.02.008","article-title":"Intracellular transport and egress of hepatitis B virus","volume":"64","author":"Blondot ML","year":"2016","unstructured":"Blondot ML, Bruss V, Kann M. Intracellular transport and egress of hepatitis B virus. J Hepatol. 2016, 64:S49-59. 10.1016\/j.jhep.2016.02.008","journal-title":"J Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007085","article-title":"Multiple roles of core protein linker in hepatitis B virus replication","volume":"14","author":"Liu K","year":"2018","unstructured":"Liu K, Luckenbaugh L, Ning X, Xi J, Hu J. Multiple roles of core protein linker in hepatitis B virus replication. PLoS Pathog. 2018, 14:e1007085. 10.1371\/journal.ppat.1007085","journal-title":"PLoS Pathog"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00798-18","article-title":"Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients","volume":"92","author":"Bai L","year":"2018","unstructured":"Bai L, Zhang X, Kozlowski M, et al.. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients. J Virol. 2018, 92:10.1128\/JVI.00798-18","journal-title":"J Virol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52824-z","article-title":"Direct interaction between the hepatitis B virus core and envelope proteins analyzed in a cellular context","volume":"9","author":"Pastor F","year":"2019","unstructured":"Pastor F, Herrscher C, Patient R, et al.. Direct interaction between the hepatitis B virus core and envelope proteins analyzed in a cellular context. Sci Rep. 2019, 9:16178. 10.1038\/s41598-019-52824-z","journal-title":"Sci Rep"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104925","article-title":"Hepatitis B virus biology and life cycle","volume":"182","author":"Tsukuda S","year":"2020","unstructured":"Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020, 182:104925. 10.1016\/j.antiviral.2020.104925","journal-title":"Antiviral Res"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01840-18","article-title":"Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and upregulate hepatitis B virus replication from cccDNA to virion in an HBx-dependent manner","volume":"93","author":"Saeed U","year":"2019","unstructured":"Saeed U, Kim J, Piracha ZZ, et al.. Parvulin 14 and Parvulin 17 Bind to HBx and cccDNA and upregulate hepatitis B virus replication from cccDNA to virion in an HBx-dependent manner. J Virol. 2019, 93:10.1128\/JVI.01840-18","journal-title":"J Virol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008459","article-title":"Role of Hepatitis B virus capsid phosphorylation in nucleocapsid disassembly and covalently closed circular DNA formation","volume":"16","author":"Luo J","year":"2020","unstructured":"Luo J, Xi J, Gao L, Hu J. Role of Hepatitis B virus capsid phosphorylation in nucleocapsid disassembly and covalently closed circular DNA formation. PLoS Pathog. 2020, 16:e1008459. 10.1371\/journal.ppat.1008459","journal-title":"PLoS Pathog"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021402","article-title":"Hepatitis B virus X and regulation of viral gene expression","volume":"6","author":"Slagle BL","year":"2016","unstructured":"Slagle BL, Bouchard MJ. Hepatitis B virus X and regulation of viral gene expression. Cold Spring Harb Perspect Med. 2016, 6:a021402. 10.1101\/cshperspect.a021402","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2018.10.010","article-title":"Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 Interaction","volume":"7","author":"Sekiba K","year":"2019","unstructured":"Sekiba K, Otsuka M, Ohno M, et al.. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 Interaction. Cell Mol Gastroenterol Hepatol. 2019, 7:297-312. 10.1016\/j.jcmgh.2018.10.010","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31240","article-title":"Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients","volume":"73","author":"Huang Q","year":"2021","unstructured":"Huang Q, Zhou B, Cai D, et al.. Rapid turnover of hepatitis B virus covalently closed circular DNA indicated by monitoring emergence and reversion of signature-mutation in treated chronic hepatitis B patients. Hepatology. 2021, 73:41-52. 10.1002\/hep.31240","journal-title":"Hepatology"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03423-19","article-title":"Involvement of host ATR-CHK1 pathway in hepatitis B Virus covalently closed circular DNA formation","volume":"11","author":"Luo J","year":"2020","unstructured":"Luo J, Luckenbaugh L, Hu H, Yan Z, Gao L, Hu J. Involvement of host ATR-CHK1 pathway in hepatitis B Virus covalently closed circular DNA formation. mBio. 2020, 11:10.1128\/mBio.03423-19","journal-title":"mBio"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/v9050125","article-title":"A role for the host DNA damage response in hepatitis B virus cccDNA formation-and beyond?","volume":"9","author":"Schreiner S","year":"2017","unstructured":"Schreiner S, Nassal M. A role for the host DNA damage response in hepatitis B virus cccDNA formation-and beyond?. Viruses. 2017, 9:10.3390\/v9050125","journal-title":"Viruses"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007742","article-title":"DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA","volume":"15","author":"Tang L","year":"2019","unstructured":"Tang L, Sheraz M, McGrane M, Chang J, Guo JT. DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. PLoS Pathog. 2019, 15:e1007742. 10.1371\/journal.ppat.1007742","journal-title":"PLoS Pathog"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3390\/v9040075","article-title":"HBV DNA integration: molecular mechanisms and clinical implications","volume":"9","author":"Tu T","year":"2017","unstructured":"Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017, 9:10.3390\/v9040075","journal-title":"Viruses"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: a review","volume":"319","author":"Tang LS","year":"2018","unstructured":"Tang LS, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018, 319:1802-13. 10.1001\/jama.2018.3795","journal-title":"JAMA"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.11.003","article-title":"PASylated interferon \u03b1 efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice","volume":"161","author":"Xia Y","year":"2019","unstructured":"Xia Y, Schlapschy M, Morath V, et al.. PASylated interferon \u03b1 efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice. Antiviral Res. 2019, 161:134-43. 10.1016\/j.antiviral.2018.11.003","journal-title":"Antiviral Res"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.08.014","article-title":"Host functions used by hepatitis B virus to complete its life cycle: implications for developing host-targeting agents to treat chronic hepatitis B","volume":"158","author":"Mitra B","year":"2018","unstructured":"Mitra B, Thapa RJ, Guo H, Block TM. Host functions used by hepatitis B virus to complete its life cycle: implications for developing host-targeting agents to treat chronic hepatitis B. Antiviral Res. 2018, 158:185-98. 10.1016\/j.antiviral.2018.08.014","journal-title":"Antiviral Res"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-9151-4_1","article-title":"Hepatitis B virus infection: overview","volume":"1179","author":"Li H","year":"2020","unstructured":"Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B virus infection: overview. Adv Exp Med Biol. 2020, 1179:1-16. 10.1007\/978-981-13-9151-4_1","journal-title":"Adv Exp Med Biol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix356","article-title":"Immunopathogenesis of hepatitis B virus","volume":"216","author":"Tseng TC","year":"2017","unstructured":"Tseng TC, Huang LR. Immunopathogenesis of hepatitis B virus. J Infect Dis. 2017, 216:S765-70. 10.1093\/infdis\/jix356","journal-title":"J Infect Dis"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2017.03.021","article-title":"Sequence analysis and functional characterization of full-length hepatitis B virus genomes from Korean cirrhotic patients with or without liver cancer","volume":"235","author":"Zhou H","year":"2017","unstructured":"Zhou H, Gewaily D, Ahn SH, et al.. Sequence analysis and functional characterization of full-length hepatitis B virus genomes from Korean cirrhotic patients with or without liver cancer. Virus Res. 2017, 235:86-95. 10.1016\/j.virusres.2017.03.021","journal-title":"Virus Res"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.3390\/genes10030182","article-title":"High frequency of either altered pre-core start codon or weakened kozak sequence in the core promoter region in hepatitis B virus A1 strains from Rwanda","volume":"10","author":"Norder H","year":"2019","unstructured":"Norder H, Twagirumugabe T, Said J, Tian Y, Tang KW, Lindh M. High frequency of either altered pre-core start codon or weakened kozak sequence in the core promoter region in hepatitis B virus A1 strains from Rwanda. Genes (Basel). 2019, 10:10.3390\/genes10030182","journal-title":"Genes (Basel)"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3161-2","article-title":"Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe","volume":"18","author":"Colagrossi L","year":"2018","unstructured":"Colagrossi L, Hermans LE, Salpini R, et al.. Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infect Dis. 2018, 18:251. 10.1186\/s12879-018-3161-2","journal-title":"BMC Infect Dis"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13175","article-title":"Early events in hepatitis B virus infection: from the cell surface to the nucleus","volume":"31","author":"Hayes CN","year":"2016","unstructured":"Hayes CN, Zhang Y, Makokha GN, Hasan MZ, Omokoko MD, Chayama K. Early events in hepatitis B virus infection: from the cell surface to the nucleus. J Gastroenterol Hepatol. 2016, 31:302-9. 10.1111\/jgh.13175","journal-title":"J Gastroenterol Hepatol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2016.05","article-title":"Hepatitis B virus molecular biology and pathogenesis","volume":"2","author":"Lamontagne RJ","year":"2016","unstructured":"Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016, 2:163-86. 10.20517\/2394-5079.2016.05","journal-title":"Hepatoma Res"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1022","article-title":"HBVdb: a knowledge database for hepatitis B virus","volume":"41","author":"Hayer J","year":"2013","unstructured":"Hayer J, Jadeau F, Del\u00e9age G, Kay A, Zoulim F, Combet C. HBVdb: a knowledge database for hepatitis B virus. Nucleic Acids Res. 2013, 41:D566-70. 10.1093\/nar\/gks1022","journal-title":"Nucleic Acids Res"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis","volume":"16","author":"Shin EC","year":"2016","unstructured":"Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016, 16:509-23. 10.1038\/nri.2016.69","journal-title":"Nat Rev Immunol"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24306","article-title":"The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation","volume":"88","author":"Sun HH","year":"2016","unstructured":"Sun HH, Zhou DF, Zhou JY. The role of DCs in the immunopathogenesis of chronic HBV infection and the methods of inducing DCs maturation. J Med Virol. 2016, 88:13-20. 10.1002\/jmv.24306","journal-title":"J Med Virol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.2217\/imt.16.3","article-title":"Hepatitis B immunopathogenesis and immunotherapy","volume":"8","author":"Golsaz-Shirazi F","year":"2016","unstructured":"Golsaz-Shirazi F, Shokri F. Hepatitis B immunopathogenesis and immunotherapy. Immunotherapy. 2016, 8:461-77. 10.2217\/imt.16.3","journal-title":"Immunotherapy"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.62","article-title":"Infiltrating monocytes in liver injury and repair","volume":"5","author":"Brempelis KJ","year":"2016","unstructured":"Brempelis KJ, Crispe IN. Infiltrating monocytes in liver injury and repair. Clin Transl Immunology. 2016, 5:e113. 10.1038\/cti.2016.62","journal-title":"Clin Transl Immunology"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.10.006","article-title":"NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection","volume":"70","author":"Schuch A","year":"2019","unstructured":"Schuch A, Zecher BF, M\u00fcller PA, et al.. NK-cell responses are biased towards CD16-mediated effector functions in chronic hepatitis B virus infection. J Hepatol. 2019, 70:351-60. 10.1016\/j.jhep.2018.10.006","journal-title":"J Hepatol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20121172","article-title":"Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion","volume":"210","author":"Peppa D","year":"2013","unstructured":"Peppa D, Gill US, Reynolds G, et al.. Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion. J Exp Med. 2013, 210:99-114. 10.1084\/jem.20121172","journal-title":"J Exp Med"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12597","article-title":"Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection","volume":"180","author":"Zheng Q","year":"2015","unstructured":"Zheng Q, Zhu YY, Chen J, et al.. Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection. Clin Exp Immunol. 2015, 180:499-508. 10.1111\/cei.12597","journal-title":"Clin Exp Immunol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.03.021","article-title":"Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients","volume":"154","author":"Wang X","year":"2018","unstructured":"Wang X, Dong Q, Li Q, et al.. Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients. Gastroenterology. 2018, 154:2222-36. 10.1053\/j.gastro.2018.03.021","journal-title":"Gastroenterology"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151717","article-title":"Characterization of the Treg response in the hepatitis B virus hydrodynamic injection mouse model","volume":"11","author":"Dietze KK","year":"2016","unstructured":"Dietze KK, Schimmer S, Kretzmer F, et al.. Characterization of the Treg response in the hepatitis B virus hydrodynamic injection mouse model. PLoS One. 2016, 11:e0151717. 10.1371\/journal.pone.0151717","journal-title":"PLoS One"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151218","article-title":"Interferon-\u03b3 facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance","volume":"213","author":"Zeng Z","year":"2016","unstructured":"Zeng Z, Li L, Chen Y, Wei H, Sun R, Tian Z. Interferon-\u03b3 facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance. J Exp Med. 2016, 213:1079-93. 10.1084\/jem.20151218","journal-title":"J Exp Med"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007690","article-title":"Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection","volume":"15","author":"Yang F","year":"2019","unstructured":"Yang F, Yu X, Zhou C, et al.. Hepatitis B e antigen induces the expansion of monocytic myeloid-derived suppressor cells to dampen T-cell function in chronic hepatitis B virus infection. PLoS Pathog. 2019, 15:e1007690. 10.1371\/journal.ppat.1007690","journal-title":"PLoS Pathog"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti A","year":"2016","unstructured":"Bertoletti A, Ferrari C. Adaptive immunity in HBV infection. J Hepatol. 2016, 64:S71-83. 10.1016\/j.jhep.2016.01.026","journal-title":"J Hepatol"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.13600","article-title":"Tim-3 blockade promotes iNKT cell function to inhibit HBV replication","volume":"22","author":"Xu Y","year":"2018","unstructured":"Xu Y, Wang Z, Du X, et al.. Tim-3 blockade promotes iNKT cell function to inhibit HBV replication. J Cell Mol Med. 2018, 22:3192-201. 10.1111\/jcmm.13600","journal-title":"J Cell Mol Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15226","article-title":"Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy","volume":"49","author":"Pal S","year":"2019","unstructured":"Pal S, Nandi M, Dey D, et al.. Myeloid-derived suppressor cells induce regulatory T cells in chronically HBV infected patients with high levels of hepatitis B surface antigen and persist after antiviral therapy. Aliment Pharmacol Ther. 2019, 49:1346-59. 10.1111\/apt.15226","journal-title":"Aliment Pharmacol Ther"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2016.07.013","article-title":"Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics","volume":"30","author":"Chang KM","year":"2016","unstructured":"Chang KM, Liu M. Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics. Curr Opin Pharmacol. 2016, 30:93-105. 10.1016\/j.coph.2016.07.013","journal-title":"Curr Opin Pharmacol"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1038\/srep26150","article-title":"Hepatitis B virus inhibits intrinsic RIG-I and RIG-G immune signaling via inducing miR146a","volume":"6","author":"Hou Z","year":"2016","unstructured":"Hou Z, Zhang J, Han Q, et al.. Hepatitis B virus inhibits intrinsic RIG-I and RIG-G immune signaling via inducing miR146a. Sci Rep. 2016, 6:26150. 10.1038\/srep26150","journal-title":"Sci Rep"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7950","article-title":"Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells","volume":"7","author":"Montalbano R","year":"2016","unstructured":"Montalbano R, Honrath B, Wissniowski TT, et al.. Exogenous hepatitis B virus envelope proteins induce endoplasmic reticulum stress: involvement of cannabinoid axis in liver cancer cells. Oncotarget. 2016, 7:20312-23. 10.18632\/oncotarget.7950","journal-title":"Oncotarget"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20030597","article-title":"Naturally occurring hepatitis B virus mutations leading to endoplasmic reticulum stress and their contribution to the progression of hepatocellular carcinoma","volume":"20","author":"Choi YM","year":"2019","unstructured":"Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus mutations leading to endoplasmic reticulum stress and their contribution to the progression of hepatocellular carcinoma. Int J Mol Sci. 2019, 20:10.3390\/ijms20030597","journal-title":"Int J Mol Sci"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0787-3","article-title":"ER stress regulating protein phosphatase 2A-B56\u03b3, targeted by hepatitis B virus X protein, induces cell cycle arrest and apoptosis of hepatocytes","volume":"9","author":"He C","year":"2018","unstructured":"He C, Qiu Y, Han P, et al.. ER stress regulating protein phosphatase 2A-B56\u03b3, targeted by hepatitis B virus X protein, induces cell cycle arrest and apoptosis of hepatocytes. Cell Death Dis. 2018, 9:762. 10.1038\/s41419-018-0787-3","journal-title":"Cell Death Dis"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2017-0118","article-title":"Chronic viral hepatitis and its association with liver cancer","volume":"398","author":"Tu T","year":"2017","unstructured":"Tu T, B\u00fchler S, Bartenschlager R. Chronic viral hepatitis and its association with liver cancer. Biol Chem. 2017, 398:817-37. 10.1515\/hsz-2017-0118","journal-title":"Biol Chem"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.09.028","article-title":"Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma","volume":"383","author":"Deng M","year":"2016","unstructured":"Deng M, Hou J, Hu J, et al.. Hepatitis B virus mRNAs functionally sequester let-7a and enhance hepatocellular carcinoma. Cancer Lett. 2016, 383:62-72. 10.1016\/j.canlet.2016.09.028","journal-title":"Cancer Lett"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i24.7375","article-title":"Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases","volume":"21","author":"Lamontagne J","year":"2015","unstructured":"Lamontagne J, Steel LF, Bouchard MJ. Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases. World J Gastroenterol. 2015, 21:7375-99. 10.3748\/wjg.v21.i24.7375","journal-title":"World J Gastroenterol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2016.53","article-title":"MicroRNAs and liver disease","volume":"62","author":"Otsuka M","year":"2017","unstructured":"Otsuka M, Kishikawa T, Yoshikawa T, et al.. MicroRNAs and liver disease. J Hum Genet. 2017, 62:75-80. 10.1038\/jhg.2016.53","journal-title":"J Hum Genet"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: global distribution and clinical importance","volume":"20","author":"Sunbul M","year":"2014","unstructured":"Sunbul M. Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol. 2014, 20:5427-34. 10.3748\/wjg.v20.i18.5427","journal-title":"World J Gastroenterol"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1345716","article-title":"Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J","volume":"33","author":"Liu CJ","year":"2013","unstructured":"Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis. 2013, 33:97-102. 10.1055\/s-0033-1345716","journal-title":"Semin Liver Dis"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06695.x","article-title":"Natural history of chronic hepatitis B REVEALed","volume":"26","author":"Chen CJ","year":"2011","unstructured":"Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol. 2011, 26:628-38. 10.1111\/j.1440-1746.2011.06695.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021436","article-title":"Hepatitis B virus genotypes and variants","volume":"5","author":"Lin CL","year":"2015","unstructured":"Lin CL, Kao JH. Hepatitis B virus genotypes and variants. Cold Spring Harb Perspect Med. 2015, 5:a021436. 10.1101\/cshperspect.a021436","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2008.00417.x","article-title":"HBV genotypes in India: do they influence disease severity?","volume":"39","author":"Madan K","year":"2009","unstructured":"Madan K, Batra Y, Sreenivas V, et al.. HBV genotypes in India: do they influence disease severity?. Hepatol Res. 2009, 39:157-63. 10.1111\/j.1872-034X.2008.00417.x","journal-title":"Hepatol Res"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.1885","article-title":"The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics","volume":"26","author":"Kramvis A","year":"2016","unstructured":"Kramvis A. The clinical implications of hepatitis B virus genotypes and HBeAg in pediatrics. Rev Med Virol. 2016, 26:285-303. 10.1002\/rmv.1885","journal-title":"Rev Med Virol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24489","article-title":"Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy","volume":"88","author":"Chauhan R","year":"2016","unstructured":"Chauhan R, Singh AK, Rooge S, Varshney A, Kumar M, Sarin SK. Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy. J Med Virol. 2016, 88:1364-75. 10.1002\/jmv.24489","journal-title":"J Med Virol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2020.03.011","article-title":"Consensus document of the Spanish association for study of the liver on the treatment of hepatitis B virus infection","volume":"43","author":"Rodr\u00edguez M","year":"2020","unstructured":"Rodr\u00edguez M, Buti M, Esteban R, Lens S, Prieto M, Su\u00e1rez E, Garc\u00eda-Samaniego J. Consensus document of the Spanish association for study of the liver on the treatment of hepatitis B virus infection. Gastroenterol Hepatol. 2020, 43:559-87. 10.1016\/j.gastrohep.2020.03.011","journal-title":"Gastroenterol Hepatol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000000478","article-title":"Chronic hepatitis B virus infection: disease revisit and management Recommendations","volume":"50","author":"Yuen MF","year":"2016","unstructured":"Yuen MF, Ahn SH, Chen DS, et al.. Chronic hepatitis B virus infection: disease revisit and management Recommendations. J Clin Gastroenterol. 2016, 50:286-94. 10.1097\/MCG.0000000000000478","journal-title":"J Clin Gastroenterol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0093","article-title":"Toward a complete cure for chronic hepatitis B: novel therapeutic targets for hepatitis B virus","volume":"69","author":"Kim SW","year":"2021","unstructured":"Kim SW, Yoon JS, Lee M, Cho Y. Toward a complete cure for chronic hepatitis B: novel therapeutic targets for hepatitis B virus. Clin Mol Hepatol. 2021, 69:391-9. 10.3350\/cmh.2021.0093","journal-title":"Clin Mol Hepatol"},{"key":"ref101","article-title":"Hepatitis B virus infection: what is current and new","volume":"26","author":"Peters MG","year":"2019","unstructured":"Peters MG. Hepatitis B virus infection: what is current and new. Top Antivir Med. 2019, 26:112-6.","journal-title":"Top Antivir Med"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.003","article-title":"EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure","volume":"66","author":"Wendon","year":"2017","unstructured":"Wendon, J, Cordoba J, Dhawan A, et al.. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol. 2017, 66:1047-81. 10.1016\/j.jhep.2016.12.003","journal-title":"J Hepatol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.11.037","article-title":"New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection","volume":"156","author":"Coffin CS","year":"2019","unstructured":"Coffin CS, Zhou K, Terrault NA. New and old biomarkers for diagnosis and management of chronic hepatitis B virus infection. Gastroenterology. 2019, 156:355-368.e3. 10.1053\/j.gastro.2018.11.037","journal-title":"Gastroenterology"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.04.002","article-title":"Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials","volume":"23","author":"Likhitsup A","year":"2019","unstructured":"Likhitsup A, Lok AS. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. Clin Liver Dis. 2019, 23:401-16. 10.1016\/j.cld.2019.04.002","journal-title":"Clin Liver Dis"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo G","year":"2019","unstructured":"Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019, 71:397-408. 10.1016\/j.jhep.2019.03.034","journal-title":"J Hepatol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16183307","article-title":"A global view to HBV chronic infection: evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals","volume":"16","author":"Nicolini LA","year":"2019","unstructured":"Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L. A global view to HBV chronic infection: evolving strategies for diagnosis, treatment and prevention in immunocompetent individuals. Int J Environ Res Public Health. 2019, 16:10.3390\/ijerph16183307","journal-title":"Int J Environ Res Public Health"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.03.013","article-title":"HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics","volume":"65","author":"Tada T","year":"2016","unstructured":"Tada T, Kumada T, Toyoda H, et al.. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. J Hepatol. 2016, 65:48-56. 10.1016\/j.jhep.2016.03.013","journal-title":"J Hepatol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-015-1153-1","article-title":"Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients","volume":"51","author":"Jung KS","year":"2016","unstructured":"Jung KS, Park JY, Chon YE, et al.. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol. 2016, 51:830-9. 10.1007\/s00535-015-1153-1","journal-title":"J Gastroenterol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12811","article-title":"Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-\u03b1","volume":"47","author":"Caviglia GP","year":"2017","unstructured":"Caviglia GP, Abate ML, Noviello D, et al.. Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-\u03b1. Hepatol Res. 2017, 47:747-54. 10.1111\/hepr.12811","journal-title":"Hepatol Res"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.021","article-title":"Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients","author":"Wang J","year":"2017","unstructured":"Wang J, Yu Y, Li G, et al.. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2017, 10.1016\/j.jhep.2017.08.021","journal-title":"J Hepatol"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017, 67:370-98. 10.1016\/j.jhep.2017.03.021","journal-title":"J Hepatol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault NA","year":"2018","unstructured":"Terrault NA, Lok AS, McMahon BJ, et al.. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018, 67:1560-99. 10.1002\/hep.29800","journal-title":"Hepatology"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29463","article-title":"Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant","volume":"67","author":"Halgand B","year":"2018","unstructured":"Halgand B, Desterke C, Rivi\u00e8re L, et al.. Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant. Hepatology. 2018, 67:86-96. 10.1002\/hep.29463","journal-title":"Hepatology"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12908","article-title":"Natural history of serum HBV-RNA in chronic HBV infection","volume":"25","author":"Wang J","year":"2018","unstructured":"Wang J, Yu Y, Li G, et al.. Natural history of serum HBV-RNA in chronic HBV infection. J Viral Hepat. 2018, 25:1038-47. 10.1111\/jvh.12908","journal-title":"J Viral Hepat"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13272","article-title":"Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B","volume":"27","author":"van Campenhout MJ","year":"2020","unstructured":"van Campenhout MJ, van B\u00f6mmel F, Pfefferkorn M, et al.. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat. 2020, 27:610-9. 10.1111\/jvh.13272","journal-title":"J Viral Hepat"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy","volume":"18","author":"Fan R","year":"2020","unstructured":"Fan R, Zhou B, Xu M, et al.. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy. Clin Gastroenterol Hepatol. 2020, 18:719-727.e7. 10.1016\/j.cgh.2019.07.046","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3707","article-title":"Association of hepatitis B virus DNA level and follow-up interval with hepatocellular carcinoma recurrence","volume":"3","author":"Wang W","year":"2020","unstructured":"Wang W, Tian SL, Wang H, Shao CC, Wang YZ, Li YL. Association of hepatitis B virus DNA level and follow-up interval with hepatocellular carcinoma recurrence. JAMA Netw Open. 2020, 3:e203707. 10.1001\/jamanetworkopen.2020.3707","journal-title":"JAMA Netw Open"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8091416","article-title":"Recent advances in understanding, diagnosing, and treating hepatitis B virus infection","volume":"8","author":"Rybicka M","year":"2020","unstructured":"Rybicka M, Bielawski KP. Recent advances in understanding, diagnosing, and treating hepatitis B virus infection. Microorganisms. 2020, 8:10.3390\/microorganisms8091416","journal-title":"Microorganisms"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.07.041","article-title":"Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning","volume":"35","author":"Wei R","year":"2018","unstructured":"Wei R, Wang J, Wang X, et al.. Clinical prediction of HBV and HCV related hepatic fibrosis using machine learning. EBioMedicine. 2018, 35:124-32. 10.1016\/j.ebiom.2018.07.041","journal-title":"EBioMedicine"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6915850","article-title":"Using machine learning algorithms to predict hepatitis B surface antigen seroclearance","volume":"2019","author":"Tian X","year":"2019","unstructured":"Tian X, Chong Y, Huang Y, et al.. Using machine learning algorithms to predict hepatitis B surface antigen seroclearance. Comput Math Methods Med. 2019, 2019:6915850. 10.1155\/2019\/6915850","journal-title":"Comput Math Methods Med"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-017-1602-3","article-title":"A machine learning approach for viral genome classification","volume":"18","author":"Remita MA","year":"2017","unstructured":"Remita MA, Halioui A, Malick Diouara AA, Daigle B, Kiani G, Diallo AB. A machine learning approach for viral genome classification. BMC Bioinformatics. 2017, 18:208. 10.1186\/s12859-017-1602-3","journal-title":"BMC Bioinformatics"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55445-8","article-title":"Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts","volume":"9","author":"Mueller-Breckenridge AJ","year":"2019","unstructured":"Mueller-Breckenridge AJ, Garcia-Alcalde F, Wildum S, et al.. Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts. Sci Rep. 2019, 9:18892. 10.1038\/s41598-019-55445-8","journal-title":"Sci Rep"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9494","article-title":"Examining the key genes and pathways in hepatocellular carcinoma development from hepatitis B virus\u2011positive cirrhosis","volume":"18","author":"Chen QF","year":"2018","unstructured":"Chen QF, Xia JG, Li W, Shen LJ, Huang T, Wu P. Examining the key genes and pathways in hepatocellular carcinoma development from hepatitis B virus\u2011positive cirrhosis. Mol Med Rep. 2018, 18:4940-50. 10.3892\/mmr.2018.9494","journal-title":"Mol Med Rep"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00046-19","article-title":"Hepatitis B virus: advances in prevention, diagnosis, and therapy","volume":"33","author":"Nguyen MH","year":"2020","unstructured":"Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020, 33:10.1128\/CMR.00046-19","journal-title":"Clin Microbiol Rev"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.04.091","article-title":"Should treatment indications for chronic hepatitis B be expanded?","volume":"19","author":"Jeng WJ","year":"2021","unstructured":"Jeng WJ, Lok AS. Should treatment indications for chronic hepatitis B be expanded?. Clin Gastroenterol Hepatol. 2021, 19:2006-14. 10.1016\/j.cgh.2020.04.091","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference\u2021","volume":"72","author":"Cornberg M","year":"2020","unstructured":"Cornberg M, Lok AS, Terrault NA, Zoulim F. Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference\u2021. J Hepatol. 2020, 72:539-57. 10.1016\/j.jhep.2019.11.003","journal-title":"J Hepatol"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis B s antigen","volume":"18","author":"Alawad AS","year":"2020","unstructured":"Alawad AS, Auh S, Suarez D, Ghany MG. Durability of spontaneous and treatment-related loss of hepatitis B s antigen. Clin Gastroenterol Hepatol. 2020, 18:700-9. 10.1016\/j.cgh.2019.07.018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14365","article-title":"Hepatitis B: who to treat? A critical review of international guidelines","volume":"40","author":"Huang DQ","year":"2020","unstructured":"Huang DQ, Lim SG. Hepatitis B: who to treat? A critical review of international guidelines. Liver Int. 2020, 40:5-14. 10.1111\/liv.14365","journal-title":"Liver Int"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8983.1","article-title":"Recent advances in understanding and diagnosing hepatitis B virus infection","volume":"5","author":"Fourati S","year":"2016","unstructured":"Fourati S, Pawlotsky JM. Recent advances in understanding and diagnosing hepatitis B virus infection. F1000Res. 2016, 5:10.12688\/f1000research.8983.1","journal-title":"F1000Res"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15581","article-title":"Review article: clinical pharmacology of current and investigational hepatitis B virus therapies","volume":"51","author":"Smolders EJ","year":"2020","unstructured":"Smolders EJ, Burger DM, Feld JJ, Kiser JJ. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther. 2020, 51:231-43. 10.1111\/apt.15581","journal-title":"Aliment Pharmacol Ther"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.09.076","article-title":"Hepatitis B vaccine and the need for a booster dose after primary vaccination","volume":"35","author":"Pileggi C","year":"2017","unstructured":"Pileggi C, Papadopoli R, Bianco A, Pavia M. Hepatitis B vaccine and the need for a booster dose after primary vaccination. Vaccine. 2017, 35:6302-7. 10.1016\/j.vaccine.2017.09.076","journal-title":"Vaccine"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.05.002","article-title":"Hepatitis B virus update","volume":"23","author":"Hassanein TI","year":"2019","unstructured":"Hassanein TI. Hepatitis B virus update. Clin Liver Dis. 2019, 23:xiii-xiv. 10.1016\/j.cld.2019.05.002","journal-title":"Clin Liver Dis"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2019.1686975","article-title":"Updates in the management of hepatitis B in children","volume":"13","author":"Lai MW","year":"2019","unstructured":"Lai MW, Chang MH. Updates in the management of hepatitis B in children. Expert Rev Gastroenterol Hepatol. 2019, 13:1065-76. 10.1080\/17474124.2019.1686975","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1732166","article-title":"Hepatitis B vaccine development and implementation","volume":"16","author":"Zhao H","year":"2020","unstructured":"Zhao H, Zhou X, Zhou YH. Hepatitis B vaccine development and implementation. Hum Vaccin Immunother. 2020, 16:1533-44. 10.1080\/21645515.2020.1732166","journal-title":"Hum Vaccin Immunother"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2019.04.006","article-title":"Drugs in the pipeline for HBV","volume":"23","author":"Lopatin U","year":"2019","unstructured":"Lopatin U. Drugs in the pipeline for HBV. Clin Liver Dis. 2019, 23:535-55. 10.1016\/j.cld.2019.04.006","journal-title":"Clin Liver Dis"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1480","article-title":"Chronic viral hepatitis: current management and future directions","volume":"4","author":"Do A","year":"2020","unstructured":"Do A, Reau NS. Chronic viral hepatitis: current management and future directions. Hepatol Commun. 2020, 4:329-41. 10.1002\/hep4.1480","journal-title":"Hepatol Commun"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning GC","year":"2019","unstructured":"Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019, 18:827-44. 10.1038\/s41573-019-0037-0","journal-title":"Nat Rev Drug Discov"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study","volume":"67","author":"Berg T","year":"2017","unstructured":"Berg T, Simon KG, Mauss S, et al.. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017, 67:918-24. 10.1016\/j.jhep.2017.07.012","journal-title":"J Hepatol"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0049","article-title":"Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop","volume":"26","author":"Yim HJ","year":"2020","unstructured":"Yim HJ, Kim JH, Park JY, et al.. Comparison of clinical practice guidelines for the management of chronic hepatitis B: when to start, when to change, and when to stop. Clin Mol Hepatol. 2020, 26:411-29. 10.3350\/cmh.2020.0049","journal-title":"Clin Mol Hepatol"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13040","article-title":"The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: considerations for future novel therapeutics","volume":"26","author":"Gill US","year":"2019","unstructured":"Gill US, Kennedy PT. The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: considerations for future novel therapeutics. J Viral Hepat. 2019, 26:4-15. 10.1111\/jvh.13040","journal-title":"J Viral Hepat"},{"key":"ref141","article-title":"Hepatitis B: screening, prevention, diagnosis, and treatment","volume":"99","author":"Wilkins T","year":"2019","unstructured":"Wilkins T, Sams R, Carpenter M. Hepatitis B: screening, prevention, diagnosis, and treatment. Am Fam Physician. 2019, 99:314-23.","journal-title":"Am Fam Physician"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1583744","article-title":"Current state-of-the-art pharmacotherapy for the management of hepatitis B infection","volume":"20","author":"Tillmann HL","year":"2019","unstructured":"Tillmann HL, Samuel G. Current state-of-the-art pharmacotherapy for the management of hepatitis B infection. Expert Opin Pharmacother. 2019, 20:873-85. 10.1080\/14656566.2019.1583744","journal-title":"Expert Opin Pharmacother"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: formation, regulation and therapeutic potential","volume":"180","author":"Xia Y","year":"2020","unstructured":"Xia Y, Guo H. Hepatitis B virus cccDNA: formation, regulation and therapeutic potential. Antiviral Res. 2020, 180:104824. 10.1016\/j.antiviral.2020.104824","journal-title":"Antiviral Res"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1281","article-title":"Hepatitis B treatment: what we know now and what remains to be researched","volume":"3","author":"Suk-Fong Lok A","year":"2019","unstructured":"Suk-Fong Lok A. Hepatitis B treatment: what we know now and what remains to be researched. Hepatol Commun. 2019, 3:8-19. 10.1002\/hep4.1281","journal-title":"Hepatol Commun"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1002\/cld.883","article-title":"Reactivation of hepatitis B virus: a review of clinical guidelines","volume":"15","author":"Myint A","year":"2020","unstructured":"Myint A, Tong MJ, Beaven SW. Reactivation of hepatitis B virus: a review of clinical guidelines. Clin Liver Dis (Hoboken). 2020, 15:162-7. 10.1002\/cld.883","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.36290\/vnl.2019.095","article-title":"Current view on hepatitis B diagnosis and therapy","volume":"65","author":"Husa P","year":"2019","unstructured":"Husa P. Current view on hepatitis B diagnosis and therapy. Vnitr Lek. 2019, 65:546-51. 10.36290\/vnl.2019.095","journal-title":"Vnitr Lek"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30119-0","article-title":"A global scientific strategy to cure hepatitis B","volume":"4","author":"Revill PA","year":"2019","unstructured":"Revill PA, Chisari FV, Block JM, et al.. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019, 4:545-58. 10.1016\/S2468-1253(19)30119-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13003","article-title":"Hepatitis B virus: new therapeutic perspectives","volume":"36","author":"Lin CL","year":"2016","unstructured":"Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int. 2016, 36:85-92. 10.1111\/liv.13003","journal-title":"Liver Int"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13694","article-title":"Review article: novel therapies for hepatitis B virus cure - advances and perspectives","volume":"44","author":"Lin CL","year":"2016","unstructured":"Lin CL, Kao JH. Review article: novel therapies for hepatitis B virus cure - advances and perspectives. Aliment Pharmacol Ther. 2016, 44:213-22. 10.1111\/apt.13694","journal-title":"Aliment Pharmacol Ther"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13656","article-title":"Towards HBV curative therapies","volume":"38","author":"Schinazi RF","year":"2018","unstructured":"Schinazi RF, Ehteshami M, Bassit L, Asselah T. Towards HBV curative therapies. Liver Int. 2018, 38:102-14. 10.1111\/liv.13656","journal-title":"Liver Int"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i23.7084","article-title":"Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA","volume":"21","author":"Ohno M","year":"2015","unstructured":"Ohno M, Otsuka M, Kishikawa T, Yoshikawa T, Takata A, Koike K. Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA. World J Gastroenterol. 2015, 21:7084-8. 10.3748\/wjg.v21.i23.7084","journal-title":"World J Gastroenterol"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-015-3660-x","article-title":"CRISPR\/Cas9-based tools for targeted genome editing and replication control of HBV","volume":"30","author":"Peng C","year":"2015","unstructured":"Peng C, Lu M, Yang D. CRISPR\/Cas9-based tools for targeted genome editing and replication control of HBV. Virol Sin. 2015, 30:317-25. 10.1007\/s12250-015-3660-x","journal-title":"Virol Sin"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2017.01.003","article-title":"Advances with using CRISPR\/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus","volume":"244","author":"Moyo B","year":"2018","unstructured":"Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P. Advances with using CRISPR\/Cas-mediated gene editing to treat infections with hepatitis B virus and hepatitis C virus. Virus Res. 2018, 244:311-20. 10.1016\/j.virusres.2017.01.003","journal-title":"Virus Res"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2016.05.006","article-title":"Control and eradication strategies of hepatitis B virus","volume":"24","author":"Shih C","year":"2016","unstructured":"Shih C, Chou SF, Yang CC, Huang JY, Choijilsuren G, Jhou RS. Control and eradication strategies of hepatitis B virus. Trends Microbiol. 2016, 24:739-49. 10.1016\/j.tim.2016.05.006","journal-title":"Trends Microbiol"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.023","article-title":"Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection","volume":"156","author":"Yuen MF","year":"2019","unstructured":"Yuen MF, Gane EJ, Kim DJ, et al.. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3-778 in patients with chronic HBV infection. Gastroenterology. 2019, 156:1392-1403. 10.1053\/j.gastro.2018.12.023","journal-title":"Gastroenterology"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-017-0726-2","article-title":"Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?","volume":"17","author":"Alonso S","year":"2017","unstructured":"Alonso S, Guerra AR, Carreira L, Ferrer J\u00c1, Guti\u00e9rrez ML, Fernandez-Rodriguez CM. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon?. BMC Gastroenterol. 2017, 17:168. 10.1186\/s12876-017-0726-2","journal-title":"BMC Gastroenterol"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13304","article-title":"Future anti-HBV strategies","volume":"37","author":"Gane EJ","year":"2017","unstructured":"Gane EJ. Future anti-HBV strategies. Liver Int. 2017, 37:40-4. 10.1111\/liv.13304","journal-title":"Liver Int"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox AL","year":"2020","unstructured":"Cox AL, El-Sayed MH, Kao JH, Lazarus JV, Lemoine M, Lok AS, Zoulim F. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020, 17:533-42. 10.1038\/s41575-020-0332-6","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.3390\/v12080851","article-title":"Advances with RNAi-based therapy for hepatitis B virus infection","volume":"12","author":"van den Berg F","year":"2020","unstructured":"van den Berg F, Limani SW, Mnyandu N, Maepa MB, Ely A, Arbuthnot P. Advances with RNAi-based therapy for hepatitis B virus infection. Viruses. 2020, 12:10.3390\/v12080851","journal-title":"Viruses"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-018-9912-8","article-title":"Immunological cure of HBV infection","volume":"13","author":"Lang J","year":"2019","unstructured":"Lang J, Neumann-Haefelin C, Thimme R. Immunological cure of HBV infection. Hepatol Int. 2019, 13:113-24. 10.1007\/s12072-018-9912-8","journal-title":"Hepatol Int"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14364","article-title":"Can we cure hepatitis B virus with novel direct-acting antivirals?","volume":"40","author":"Martinez MG","year":"2020","unstructured":"Martinez MG, Villeret F, Testoni B, Zoulim F. Can we cure hepatitis B virus with novel direct-acting antivirals?. Liver Int. 2020, 40:27-34. 10.1111\/liv.14364","journal-title":"Liver Int"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2017.04.012","article-title":"Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles","volume":"143","author":"Edwards TC","year":"2017","unstructured":"Edwards TC, Lomonosova E, Patel JA, et al.. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles. Antiviral Res. 2017, 143:205-17. 10.1016\/j.antiviral.2017.04.012","journal-title":"Antiviral Res"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010213","article-title":"Hepatitis B virus cure: targets and future therapies","volume":"22","author":"Lee HW","year":"2020","unstructured":"Lee HW, Lee JS, Ahn SH. Hepatitis B virus cure: targets and future therapies. Int J Mol Sci. 2020, 22:10.3390\/ijms22010213","journal-title":"Int J Mol Sci"},{"key":"ref164","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00337","article-title":"Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives","volume":"5","author":"Yang L","year":"2019","unstructured":"Yang L, Liu F, Tong X, Hoffmann D, Zuo J, Lu M. Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives. ACS Infect Dis. 2019, 5:713-24. 10.1021\/acsinfecdis.8b00337","journal-title":"ACS Infect Dis"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2018.01.008","article-title":"Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B","volume":"30","author":"Suslov A","year":"2018","unstructured":"Suslov A, Wieland S, Menne S. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. Curr Opin Virol. 2018, 30:9-17. 10.1016\/j.coviro.2018.01.008","journal-title":"Curr Opin Virol"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0769-2","article-title":"Drugs in development for hepatitis B","volume":"77","author":"Dawood A","year":"2017","unstructured":"Dawood A, Abdul Basit S, Jayaraj M, Gish RG. Drugs in development for hepatitis B. Drugs. 2017, 77:1263-80. 10.1007\/s40265-017-0769-2","journal-title":"Drugs"},{"key":"ref167","article-title":"Emerging therapies toward a functional cure for hepatitis b virus infection","volume":"14","author":"Kim WR","year":"2018","unstructured":"Kim WR. Emerging therapies toward a functional cure for hepatitis b virus infection. Gastroenterol Hepatol (N Y). 2018, 14:439-42.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00401","article-title":"Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection","volume":"11","author":"Hoogeveen RC","year":"2020","unstructured":"Hoogeveen RC, Boonstra A. Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic HBV infection. Front Immunol. 2020, 11:401. 10.3389\/fimmu.2020.00401","journal-title":"Front Immunol"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.04.015","article-title":"Hepatitis B virus - recent therapeutic advances and challenges to cure","volume":"73","author":"Mouzannar K","year":"2020","unstructured":"Mouzannar K, Liang TJ. Hepatitis B virus - recent therapeutic advances and challenges to cure. J Hepatol. 2020, 73:694-5. 10.1016\/j.jhep.2020.04.015","journal-title":"J Hepatol"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.02.063","article-title":"A new approach for therapeutic vaccination against chronic HBV infections","volume":"38","author":"Zahn T","year":"2020","unstructured":"Zahn T, Akhras S, Spengler C, Murra RO, Holzhauser T, Hildt E. A new approach for therapeutic vaccination against chronic HBV infections. Vaccine. 2020, 38:3105-20. 10.1016\/j.vaccine.2020.02.063","journal-title":"Vaccine"},{"key":"ref171","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1689745","article-title":"Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance","volume":"16","author":"Whitacre DC","year":"2020","unstructured":"Whitacre DC, Peters CJ, Sureau C, et al.. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Hum Vaccin Immunother. 2020, 16:251-68. 10.1080\/21645515.2019.1689745","journal-title":"Hum Vaccin Immunother"},{"key":"ref172","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial","volume":"16","author":"Zoulim F","year":"2020","unstructured":"Zoulim F, Fournier C, Habersetzer F, et al.. Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Hum Vaccin Immunother. 2020, 16:388-99. 10.1080\/21645515.2019.1651141","journal-title":"Hum Vaccin Immunother"},{"key":"ref173","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56842-9","article-title":"Development of a novel anti-hepatitis B virus agent via Sp1","volume":"10","author":"Hayakawa M","year":"2020","unstructured":"Hayakawa M, Umeyama H, Iwadate M, et al.. Development of a novel anti-hepatitis B virus agent via Sp1. Sci Rep. 2020, 10:47. 10.1038\/s41598-019-56842-9","journal-title":"Sci Rep"},{"key":"ref174","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-9151-4_6","article-title":"Present and future therapies for chronic hepatitis B","volume":"1179","author":"Tao Y","year":"2020","unstructured":"Tao Y, Wu D, Zhou L, et al.. Present and future therapies for chronic hepatitis B. Adv Exp Med Biol. 2020, 1179:137-86. 10.1007\/978-981-13-9151-4_6","journal-title":"Adv Exp Med Biol"},{"key":"ref175","doi-asserted-by":"publisher","DOI":"10.1177\/2049936120965027","article-title":"Advances in hepatitis B therapeutics","volume":"7","author":"Soriano V","year":"2020","unstructured":"Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis. 2020, 7:10.1177\/2049936120965027","journal-title":"Ther Adv Infect Dis"},{"key":"ref176","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103187","article-title":"New approaches to the treatment of chronic hepatitis B","volume":"9","author":"Alexopoulou A","year":"2020","unstructured":"Alexopoulou A, Vasilieva L, Karayiannis P. New approaches to the treatment of chronic hepatitis B. J Clin Med. 2020, 9:10.3390\/jcm9103187","journal-title":"J Clin Med"},{"key":"ref177","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0631","article-title":"Acute-on-chronic liver failure","volume":"20","author":"Kumar R","year":"2020","unstructured":"Kumar R, Mehta G, Jalan R. Acute-on-chronic liver failure. Clin Med (Lond). 2020, 20:501-4. 10.7861\/clinmed.2020-0631","journal-title":"Clin Med (Lond)"},{"key":"ref178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.029","article-title":"Acute-on-chronic liver failure: the challenge of PREDICTing who and when","volume":"73","author":"O'Brien A","year":"2020","unstructured":"O'Brien A, Karvellas CJ. Acute-on-chronic liver failure: the challenge of PREDICTing who and when. J Hepatol. 2020, 73:755-6. 10.1016\/j.jhep.2020.07.029","journal-title":"J Hepatol"},{"key":"ref179","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09946-3","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update","volume":"13","author":"Sarin SK","year":"2019","unstructured":"Sarin SK, Choudhury A, Sharma MK, et al.. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019, 13:353-90. 10.1007\/s12072-019-09946-3","journal-title":"Hepatol Int"},{"key":"ref180","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000201","article-title":"Drug-induced acute-on-chronic liver failure in asian patients","volume":"114","author":"Devarbhavi H","year":"2019","unstructured":"Devarbhavi H, Choudhury AK, Sharma MK, et al.. Drug-induced acute-on-chronic liver failure in asian patients. Am J Gastroenterol. 2019, 114:929-37. 10.14309\/ajg.0000000000000201","journal-title":"Am J Gastroenterol"},{"key":"ref181","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-015-0313-5","article-title":"Associations between hepatitis B virus basal core promoter\/pre-core region mutations and the risk of acute-on-chronic liver failure: a meta-analysis","volume":"12","author":"Hu F","year":"2015","unstructured":"Hu F, Bi S, Yan H, Shi Y, Sheng J. Associations between hepatitis B virus basal core promoter\/pre-core region mutations and the risk of acute-on-chronic liver failure: a meta-analysis. Virol J. 2015, 12:87. 10.1186\/s12985-015-0313-5","journal-title":"Virol J"},{"key":"ref182","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313035","article-title":"Genome-wide association study identi\ufb01es HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure","volume":"67","author":"Tan W","year":"2018","unstructured":"Tan W, Xia J, Dan Y, et al.. Genome-wide association study identi\ufb01es HLA-DR variants conferring risk of HBV-related acute-on-chronic liver failure. Gut. 2018, 67:757-66. 10.1136\/gutjnl-2016-313035","journal-title":"Gut"},{"key":"ref183","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-016-9716-7","article-title":"Association between hepatitis B virus basal core promoter\/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis","volume":"10","author":"Nian X","year":"2016","unstructured":"Nian X, Xu Z, Liu Y, Chen J, Li X, Xu D. Association between hepatitis B virus basal core promoter\/precore region mutations and the risk of hepatitis B-related acute-on-chronic liver failure in the Chinese population: an updated meta-analysis. Hepatol Int. 2016, 10:606-15. 10.1007\/s12072-016-9716-7","journal-title":"Hepatol Int"},{"key":"ref184","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2018.1426459","article-title":"Acute-on-chronic liver failure in chronic hepatitis B: an update","volume":"12","author":"Zhao RH","year":"2018","unstructured":"Zhao RH, Shi Y, Zhao H, Wu W, Sheng JF. Acute-on-chronic liver failure in chronic hepatitis B: an update. Expert Rev Gastroenterol Hepatol. 2018, 12:341-50. 10.1080\/17474124.2018.1426459","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref185","doi-asserted-by":"publisher","DOI":"10.1515\/med-2020-0207","article-title":"Clinical prediction for outcomes of patients with acute-on-chronic liver failure associated with HBV infection: a new model establishment","volume":"15","author":"Fan W","year":"2020","unstructured":"Fan W, Liao W, Luo Y, You B, Yu J, Li C. Clinical prediction for outcomes of patients with acute-on-chronic liver failure associated with HBV infection: a new model establishment. Open Med (Wars). 2020, 15:714-22. 10.1515\/med-2020-0207","journal-title":"Open Med (Wars)"},{"key":"ref186","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-020-01437-2","article-title":"A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: a retrospective cohort study","volume":"20","author":"Qiang L","year":"2020","unstructured":"Qiang L, Qin J, Sun C, et al.. A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: a retrospective cohort study. BMC Gastroenterol. 2020, 20:301. 10.1186\/s12876-020-01437-2","journal-title":"BMC Gastroenterol"},{"key":"ref187","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175332","article-title":"Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure treated with an artificial liver support system","volume":"12","author":"Fan Z","year":"2017","unstructured":"Fan Z, EnQiang C, Yao DL, et al.. Neutrophil-lymphocyte ratio predicts short term mortality in patients with hepatitis B virus-related acute-on-chronic liver failure treated with an artificial liver support system. PLoS One. 2017, 12:e0175332. 10.1371\/journal.pone.0175332","journal-title":"PLoS One"},{"key":"ref188","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-314641","article-title":"Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure","volume":"67","author":"Wu T","year":"2018","unstructured":"Wu T, Li J, Shao L, et al.. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018, 67:2181-91. 10.1136\/gutjnl-2017-314641","journal-title":"Gut"},{"key":"ref189","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14927","article-title":"HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure","volume":"48","author":"Wu D","year":"2018","unstructured":"Wu D, Sun Z, Liu X, et al.. HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure. Aliment Pharmacol Ther. 2018, 48:750-60. 10.1111\/apt.14927","journal-title":"Aliment Pharmacol Ther"},{"key":"ref190","doi-asserted-by":"publisher","DOI":"10.1159\/000495904","article-title":"Predictive value of age-bilirubin-international normalized ratio-creatinine score in short-term survival of acute-on-chronic hepatitis B liver failure","volume":"51","author":"Chen L","year":"2018","unstructured":"Chen L, Zheng J, Cai J, et al.. Predictive value of age-bilirubin-international normalized ratio-creatinine score in short-term survival of acute-on-chronic hepatitis B liver failure. Cell Physiol Biochem. 2018, 51:2484-95. 10.1159\/000495904","journal-title":"Cell Physiol Biochem"},{"key":"ref191","doi-asserted-by":"publisher","DOI":"10.1172\/JCI130197","article-title":"Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure","volume":"130","author":"Wu D","year":"2020","unstructured":"Wu D, Zhang S, Xie Z, et al.. Plasminogen as a prognostic biomarker for HBV-related acute-on-chronic liver failure. J Clin Invest. 2020, 130:2069-80. 10.1172\/JCI130197","journal-title":"J Clin Invest"},{"key":"ref192","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5062873","article-title":"Value of liver regeneration in predicting short-term prognosis for patients with hepatitis B-related acute-on-chronic liver failure","volume":"2020","author":"Wang X","year":"2020","unstructured":"Wang X, Sun M, Yang X, et al.. Value of liver regeneration in predicting short-term prognosis for patients with hepatitis B-related acute-on-chronic liver failure. Biomed Res Int. 2020, 2020:5062873. 10.1155\/2020\/5062873","journal-title":"Biomed Res Int"},{"key":"ref193","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21762","article-title":"A prognostic model for hepatitis B acute-on-chronic liver failure patients treated using a plasma exchange-centered liver support system","volume":"35","author":"Xie Z","year":"2020","unstructured":"Xie Z, Violetta L, Chen E, et al.. A prognostic model for hepatitis B acute-on-chronic liver failure patients treated using a plasma exchange-centered liver support system. J Clin Apher. 2020, 35:94-103. 10.1002\/jca.21762","journal-title":"J Clin Apher"},{"key":"ref194","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53029-0","article-title":"Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: classification and regression tree analysis","volume":"9","author":"Huang K","year":"2019","unstructured":"Huang K, Ji F, Xie Z, et al.. Artificial liver support system therapy in acute-on-chronic hepatitis B liver failure: classification and regression tree analysis. Sci Rep. 2019, 9:16462. 10.1038\/s41598-019-53029-0","journal-title":"Sci Rep"},{"key":"ref195","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.09.009","article-title":"World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure","volume":"45","author":"Mu X","year":"2021","unstructured":"Mu X, Tong J, Xu X, et al.. World Gastroenterology Organisation classification and a new type-based prognostic model for hepatitis B virus-related acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol. 2021, 45:101548. 10.1016\/j.clinre.2020.09.009","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref196","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001038","article-title":"Tenofovir versus entecavir for the treatment of acute-on-chronic liver failure due to reactivation of chronic hepatitis B with genotypes B and C","volume":"53","author":"Wan YM","year":"2019","unstructured":"Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Wu XN, Yang JH. Tenofovir versus entecavir for the treatment of acute-on-chronic liver failure due to reactivation of chronic hepatitis B with genotypes B and C. J Clin Gastroenterol. 2019, 53:e171-7. 10.1097\/MCG.0000000000001038","journal-title":"J Clin Gastroenterol"},{"key":"ref197","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13497","article-title":"Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: a case-control matched analysis","volume":"50","author":"Yang L","year":"2020","unstructured":"Yang L, Wu T, Li J, et al.. Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: a case-control matched analysis. Hepatol Res. 2020, 50:656-70. 10.1111\/hepr.13497","journal-title":"Hepatol Res"},{"key":"ref198","doi-asserted-by":"publisher","DOI":"10.1111\/1751-2980.12691","article-title":"Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: a 10-year cohort study in a university hospital in East China","volume":"20","author":"Huang C","year":"2019","unstructured":"Huang C, Yu KK, Zheng JM, Li N. Steroid treatment in patients with acute-on-chronic liver failure precipitated by hepatitis B: a 10-year cohort study in a university hospital in East China. J Dig Dis. 2019, 20:38-44. 10.1111\/1751-2980.12691","journal-title":"J Dig Dis"},{"key":"ref199","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000020604","article-title":"Glucocorticoid versus traditional therapy for hepatitis B virus-related acute-on-chronic liver failure: a systematic review and meta-analysis","volume":"99","author":"Gao R","year":"2020","unstructured":"Gao R, Li Y, Cao Y, Zheng R, Tang L, Yang J, Lu X. Glucocorticoid versus traditional therapy for hepatitis B virus-related acute-on-chronic liver failure: a systematic review and meta-analysis. Medicine (Baltimore). 2020, 99:e20604. 10.1097\/MD.0000000000020604","journal-title":"Medicine (Baltimore)"},{"key":"ref200","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01814-4","article-title":"The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial","volume":"18","author":"Jia L","year":"2020","unstructured":"Jia L, Xue R, Zhu Y, et al.. The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial. BMC Med. 2020, 18:383. 10.1186\/s12916-020-01814-4","journal-title":"BMC Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/75478-critical-updates-on-chronic-hepatitis-b-virus-infection-in-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:32:50Z","timestamp":1707507170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/75478-critical-updates-on-chronic-hepatitis-b-virus-infection-in-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":200,"URL":"https:\/\/doi.org\/10.7759\/cureus.19152","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,30]]}}}